Drug
Pasireotide Long Acting Release
Pasireotide Long Acting Release: highest development phase Phase 2, developed by United Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Pasireotide Long Acting Release (LAR) NCT01253161 | Phase 2 | Neuroendocrine Tumors |
Latest
No recent events.
Follow Pasireotide Long Acting Release on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.